Claims
- 1. A compound of formula I
- 2. A compound of claim 1 wherein R1 is hydrogen, hydroxy, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms.
- 3. A compound of claim 1 wherein R2 is hydrogen, hydroxy, halo, cyano, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms.
- 4. A compound of claim 1 wherein R3, R4 and R5 are, independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of one to six carbon atoms, and alkoxy of one to six carbon atoms.
- 5. A compound of claim 1 wherein R1, R2, R3, R4 and R5 are, independently selected from hydrogen, halogen and cyano.
- 6. (Canceled)
- 7. A compound of claim 1 wherein Z is CR8.
- 8. A compound of claim 7 wherein R8 is hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms.
- 9. (Canceled)
- 10. A compound of claim 2 in which R2 and R6 are hydrogen, and R3, R4 and R5 are independently selected from hydrogen, halo and cyano, n is 0 and the dotted line represents a double bond; or a pharmaceutically acceptable salt thereof.
- 11. A compound of claim 1 which is the R stereoisomer substantially free of the S stereoisomer.
- 12-14. (Canceled)
- 15. An intermediate of the formula
- 16. A compound of claim 15 which is:
Toluene-4-sulfonic acid 7,8-dihydro-6H-5-oxa-1-aza-phenanthren-6-ylmethyl ester; (6S)-Toluene-4-sulfonic acid 7,8-dihydro-6H-5-oxa-1-aza-phenanthren-6-ylmethyl ester; or (6R)-Toluene-4-sulfonic acid 7,8-dihydro-6H-5-oxa-1-aza-phenanthren-6-ylmethyl ester.
- 17. A method of treating a subject suffering from a condition selected from the group consisting of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addition, and sexual dysfunction, which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 18. The method of claim 17 wherein the condition is depression.
- 19. The method of claim 17 wherein the condition is obsessive compulsive disorder, panic attacks, generalized anxiety disorder or social anxiety disorder.
- 20. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I
- 21. The method of claim 17 wherein the condition is anxiety, post-traumatic stress disorder or attention-deficit disorder.
- 22. The method of claim 17 wherein the condition is premenstrual dysphoric disorder or vasometer flushing.
- 23. The method of claim 17 wherein the condition is obesity or eating disorders.
- 24. The method of claim 23 wherein the eating disorder is anorexia nervosa or bulimia nervosa.
- 25. The method of claim 17 wherein the condition is cocaine or alcohol addiction.
- 26. The method of claim 17 wherein the condition is sexual dysfunction.
- 27. A method of blocking the reuptake of serotonin in a subject comprising comprising providing to the subject an effective amount of a compound of claim 1.
- 28. A method of agonizing the 5HT1A receptor in a subject comprising providing to the subject an effective amount of a compound of claim 1.
Parent Case Info
[0001] This application claims priority from co-pending provisional application Ser. No. 60/307,667, filed on Jul. 25, 2001, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60307667 |
Jul 2001 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10201862 |
Jul 2002 |
US |
Child |
10878777 |
Jun 2004 |
US |